Pharmacy EBITDA Multiples: 2.5x–5.5x — What Buyers Pay (2026)
Independent pharmacies sell for 3x–5.5x EBITDA depending on prescription volume, specialty services, payer mix, and compliance history. Here is what moves the needle.
Independent pharmacy valuations in the lower middle market typically range from 3x to 5.5x EBITDA, with prescription file strength, specialty or compounding revenue, and clean DEA compliance driving the upper end. Buyers price in PBM reimbursement risk, DIR fee exposure, and staff retention. Inventory is generally priced separately at cost, and earnouts tied to patient file retention are common in structured deals.
Pharmacy EBITDA Multiples (2026)
| Practice Size | EBITDA Range | Multiple Range | Notes |
|---|---|---|---|
| Distressed or High-Risk | $80K–$200K | 2.5x–3.0x | Declining script volume, heavy PBM dependency, DIR fee exposure, or compliance issues. Buyers require significant price concessions and earnout protection. |
| Stable Independent | $200K–$400K | 3.0x–4.0x | Established patient base with steady refill rates, clean compliance record, but limited specialty revenue and owner-dependent operations. |
| Strong Independent with Niche Services | $400K–$600K | 4.0x–4.75x | Compounding, LTC, or specialty contracts adding margin diversity. Licensed pharmacist staff willing to stay post-close. Recurring institutional revenue. |
| Premium Specialty or LTC Platform | $600K–$900K+ | 4.75x–5.5x | Documented LTC or hospice contracts, strong compounding revenue, transferable systems, and a patient base with low churn command top-tier pricing. |
Valuation Drivers — What Makes Your Multiple Higher or Lower
The spread between 3.5x and 6.5x is not random. These seven factors determine where your firm lands.
Prescription File Quality
HighActive patient count, 30-day refill rates, and top drug category mix directly determine prescription file value, often the largest asset in the transaction.
Specialty and Compounding Revenue
HighPharmacies with compounding or specialty dispensing reduce PBM dependency, generate higher margins, and command meaningfully higher EBITDA multiples from strategic buyers.
PBM Contract and DIR Fee Exposure
HighHeavy reliance on low-margin generics with high DIR fee clawbacks compresses reported EBITDA and signals ongoing margin risk that buyers discount aggressively.
DEA and Regulatory Compliance History
MediumClean DEA registration, state board standing, and no audit findings from CMS or PBMs are baseline requirements. Any violations reduce buyer pool and compress multiples.
Staff Retention and Pharmacist Continuity
MediumA licensed pharmacist willing to remain post-close significantly reduces transition risk. Owner-only operations with no backup pharmacist are a material valuation discount.
Recent Market Trends
PBM reimbursement compression and rising DIR fees have pushed more independent pharmacy owners to accelerate exit timelines, increasing deal flow in 2023–2024. PE-backed platforms are selectively acquiring compounding and LTC pharmacies at premium multiples, while standard retail pharmacies face tighter buyer scrutiny. SBA 7(a) financing remains the dominant deal structure for individual buyers, with seller carry of 10–20% increasingly required to close valuation gaps.
Who Buys Pharmacys in 2026
Individual Operator / Search Fund
Entrepreneurship through acquisition (ETA), first-time buyers, industry-adjacent operators
What they want: Stable, transferable cash flow in a Pharmacy. SBA-eligible business, strong revenue quality, and a seller available for a 12–18 month transition.
Pros for seller
- +SBA 7(a) financing means 10% buyer equity — faster than waiting for institutional capital
- +Buyer works inside the business, maintaining client and staff relationships
- +Deal structure is typically straightforward: cash at close plus seller note
Cons for seller
- −Lower multiples than PE buyers — typically at the low-to-mid end of the range
- −Requires meaningful seller involvement post-close for transition
- −SBA approval timeline adds 60–90 days to closing
PE-Backed Roll-Up Platform
Private equity consolidators building a Pharmacy portfolio, regional or national platforms
What they want: Scale, operational quality, and geographic coverage. Strong revenue quality with minimal owner dependency. Clean financials, documented systems, and staff who can operate without the selling owner.
Pros for seller
- +All-cash close with no SBA financing contingency or approval delay
- +Highest multiples available for premium businesses
- +Equity rollover option — seller keeps 10–30% stake and participates in platform exit
Cons for seller
- −Extensive 90–150 day due diligence process
- −Post-close integration into a larger platform changes operating culture
- −Usually requires seller to remain in a leadership role for 12–24 months
Strategic Acquirer
Larger Pharmacy operators, adjacent-industry buyers adding capacity or geography
What they want: Client relationships, staff, and market position that complement existing operations. revenue quality is especially valuable when it fills a gap the buyer cannot build organically.
Pros for seller
- +Can pay above-model multiples for strong strategic fit
- +Buyer already understands the business — diligence moves faster
- +Shorter transition requirement when operational overlap exists
Cons for seller
- −Fewer competing buyers — less negotiating leverage
- −Non-compete scope is typically broader than PE or individual deals
- −Operations and brand may change significantly post-close
Sample Pharmacy Transactions
Single-location retail pharmacy in the Southeast with strong 30-day refill rates, clean compliance, and a licensed staff pharmacist retained post-close.
$320,000
EBITDA
3.75x
Multiple
$1,200,000
Price
Independent compounding pharmacy with institutional contracts and documented LTC facility relationships, acquired by a regional pharmacy chain expanding specialty services.
$580,000
EBITDA
5.0x
Multiple
$2,900,000
Price
Owner-operated retail pharmacy with declining script volume and heavy PBM exposure, sold via asset purchase with earnout tied to 12-month patient retention.
$160,000
EBITDA
2.75x
Multiple
$440,000
Price
EBITDA Valuation Estimator
Get your Pharmacy business value range instantly
Industry: Pharmacy · Multiples based on 3.0x–4.0x (Stable Independent)
Powered by DealFlow OS
dealflow-os.com · Free M&A tools for every stage of the deal
How to Use These Multiples
For Sellers: 4-Step Valuation Walkthrough
- 1
Compile three years of P&L statements and tax returns that reconcile line by line — SBA lenders and institutional buyers both require this, and any unexplained gap triggers diligence delays or price renegotiation.
- 2
Build a normalized EBITDA schedule with every add-back documented: owner W-2 above a market-rate manager salary, personal expenses, one-time items, and non-recurring costs. Undocumented add-backs get cut.
- 3
Address your owner dependency before going to market — this is the most common reason Pharmacy businesses receive offers at the low end of the 2.5x–5.5x range. Buyers identify it in diligence and reprice accordingly.
- 4
Quantify and document your revenue quality with supporting records: contracts, renewal histories, and client revenue breakdowns. This is the primary evidence for commanding a premium multiple — have it ready before the first buyer call.
For Buyers: Validate the Asking Multiple
- 1
Request trailing 12-month and 3-year P&L with bank statement backup before making an offer. If a Pharmacy seller cannot produce reconciled financials, that signals what the full diligence process will look like.
- 2
Verify the revenue quality claims independently — pull contract copies, renewal documentation, and client-level revenue data. This is the primary driver of whether this Pharmacy is worth 5.5x or 2.5x.
- 3
Assess owner dependency directly: ask which revenue or client relationships depend on the current owner personally, and what the transition plan is. An exit-ready seller has already worked through this.
- 4
Model your SBA debt service against verified EBITDA before signing the LOI. At current rates, a $1M SBA 7(a) loan runs approximately $13,000/month over 10 years — the business needs at least 1.25x debt service coverage after a market-rate manager salary.
Frequently Asked Questions
How is an independent pharmacy valued beyond EBITDA?
Prescription file value, inventory at cost, and real estate or lease terms are priced separately. The prescription file is often the largest asset and is valued on active patient count and refill rates.
Do PBM contracts transfer to a new pharmacy owner?
Not automatically. Change-of-ownership provisions in PBM contracts must be reviewed carefully. Some networks require reapplication and credentialing, which can delay closing and create revenue gap risk.
Can I use an SBA loan to buy an independent pharmacy?
Yes. Pharmacies are SBA 7(a) eligible. Most deals use SBA financing with a 10–15% buyer down payment, seller carry of 10–20%, and earnouts tied to prescription volume retention over 12–24 months.
What kills pharmacy deal value most often?
Declining script volume, high DIR fee exposure, DEA or state board compliance issues, and an owner-only operation with no licensed backup pharmacist are the most common valuation killers buyers cite.
More Pharmacy Guides
Related Reading
Find Pharmacy businesses at the right price
DealFlow OS surfaces acquisition targets with seller signals and outreach angles. Free to join.
No credit card required